New pill targets DNA repair in Hard-to-Treat cancers
NCT ID NCT06606990
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 29 times
Summary
This early-stage study tests a new oral drug called pidnarulex in 40 adults with advanced solid tumors that have spread and stopped responding to standard treatments. The drug works by blocking a key enzyme cancer cells need to divide and repair their DNA. The main goal is to see how the drug affects a DNA repair marker (RAD51) and to check safety and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Institute Developmental Therapeutics Clinic
RECRUITINGBethesda, Maryland, 20892, United States
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.